---
title: "Citi Remains a Buy on Vor Biopharma (VOR)"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/295823649.md"
description: "Citi analyst Geoff Meacham maintained a Buy rating on Vor Biopharma (VOR) with a $50 price target. This follows a recent Buy from H.C. Wainwright, while Wedbush kept a Hold rating. Meacham, who covers healthcare stocks including Merck and Pfizer, has a 15.7% average return and 60.63% success rate on recommendations."
datetime: "2026-08-13T15:55:43.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/295823649.md)
  - [en](https://longbridge.com/en/news/295823649.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/295823649.md)
generator: "portal-rs"
---

# Citi Remains a Buy on Vor Biopharma (VOR)

Citi analyst Geoff Meacham maintained a Buy rating on Vor Biopharma today and set a price target of $50.00.

### Claim 55% Off TipRanks

-   Unlock powerful investing tools with TipRanks Premium to make smarter, more confident investment decisions
-   Subscribe to TipRanks Smart Investor Newsletter, and discover new investing opportunities with data-backed stock picks

Meacham covers the Healthcare sector, focusing on stocks such as Merck & Company, Pfizer, and Eli Lilly & Co. According to TipRanks, Meacham has an average return of 15.7% and a 60.63% success rate on recommended stocks. 

In addition to Citi, Vor Biopharma also received a Buy from H.C. Wainwright’s Swayampakula Ramakanth in a report issued yesterday. However, on the same day, Wedbush maintained a Hold rating on Vor Biopharma (NASDAQ: VOR).

### Related Stocks

- [VOR.US](https://longbridge.com/en/quote/VOR.US.md)
- [C.US](https://longbridge.com/en/quote/C.US.md)
- [MRK.US](https://longbridge.com/en/quote/MRK.US.md)
- [PFE.US](https://longbridge.com/en/quote/PFE.US.md)
- [LLY.US](https://longbridge.com/en/quote/LLY.US.md)
- [C-R.US](https://longbridge.com/en/quote/C-R.US.md)

## Related News & Research

- [Vor Biopharma reports Q2 results](https://longbridge.com/en/news/295613869.md)
- [Vor Bio Reports Second Quarter 2026 Financial Results and Provides Corporate Update | VOR Stock News](https://longbridge.com/en/news/295545637.md)
- [Vor Bio Q2 FY26 net loss narrows to $62.8 million; R&D expenses drop to $25.9 million](https://longbridge.com/en/news/295544536.md)
- [Barclays Sticks to Its Buy Rating for Prosus (PROSF)](https://longbridge.com/en/news/296063490.md)
- [J.P. Morgan Reaffirms Their Hold Rating on Pennantpark Investment (PNNT)](https://longbridge.com/en/news/296176376.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**